Prostate Cancer - Results from #1900

AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity Against Prostate Cancer. November 8, 2023

Transposable Elements Are Co-opted as Oncogenic Regulatory Elements by Lineage-Specific Transcription Factors in Prostate Cancer. November 8, 2023

Prostate Cancer in Transgender Women: Epidemiology, Clinical Characteristics, and Management Challenges. November 8, 2023

Development and Validation of a Tool to Identify Patients Diagnosed With Castration-Resistant Prostate Cancer. November 8, 2023

Comparison of salvage radical prostatectomy vs. salvage ablation therapy for biopsyproven radio-recurrent localized prostate cancer. November 8, 2023

Can MRI Help Inform Which Men with a History of Multifocal High Grade Prostatic Intraepithelial Neoplasia or Atypical Small Acinar Proliferation Remain at an Elevated Risk for Clinically Significant Prostate Cancer? November 8, 2023

A conserved mechanism for JNK-mediated loss of Notch function in advanced prostate cancer. November 8, 2023

Recruitment Target Achieved for Phase II SAR-Bombesin Prostate Cancer Trial November 7, 2023

Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Radioligand Therapy. November 7, 2023

Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand? November 7, 2023

Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry. November 7, 2023

Effect of omega-3 fatty acid diet on prostate cancer progression and cholesterol efflux in tumor-associated macrophages-dependence on GPR120. November 7, 2023

Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate. November 7, 2023

Effect of Pelvic External Beam Radiation Therapy on Bone Mineral Density: A Secondary Analysis of a Phase III Randomized Controlled Trial. November 7, 2023

Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. November 7, 2023

Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer. November 7, 2023

Personalized Medicine for Metastatic Prostate Cancer: The Paradigm of PARP Inhibitors. November 7, 2023

Understanding Current Demographics, Practice Patterns, and Concerns of Women in Urology: Analysis From the 2022 Society of Women in Urology Census Task Force November 6, 2023

New Radiopharmaceutical Shows Antitumor Activity in Patients with Advanced Prostate Cancer November 6, 2023

Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy. November 6, 2023

Page 96 of 1439